Galloylpaeoniflorin

Synonyms: 6'-O-Galloyl paeoniflorin
Galloylpaeoniflorin(6'-O-Galloyl paeoniflorin)是一种具有口服活性的 Paeoniflorin(MS-U97441)没食子酰化衍生物,存在于芍药根中,具有多种抗炎和抗氧化活性,可抑制 RANKL 诱导的 ERK、JNK、c-Fos、c-Jun 和 NFATc1 激活并降低破骨细胞特异性基因表达,激活 Nrf2 和 PI3K/Akt 通路、抑制 NF-κB 激活并清除活性氧(ROS)以减少氧化性 DNA、脂质和蛋白质损伤,还能减轻神经炎症、抑制细胞凋亡(apoptosis)、缓解幽门螺杆菌诱导的胃黏膜损伤以及 UVB 诱导的细胞损伤,可用于骨质疏松症、胃炎、缺血性脑卒中及皮肤病的相关研究。
产品编号: MS-K13761 纯度: 98.30% CAS No.: 122965-41-7 分子式: C30H32O15 分子量: 632.57
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

Galloylpaeoniflorin(6'-O-Galloyl paeoniflorin)是一种具有口服活性的 Paeoniflorin(MS-U97441)没食子酰化衍生物,存在于芍药根中,具有多种抗炎和抗氧化活性,可抑制 RANKL 诱导的 ERK、JNK、c-Fos、c-Jun 和 NFATc1 激活并降低破骨细胞特异性基因表达,激活 Nrf2 和 PI3K/Akt 通路、抑制 NF-κB 激活并清除活性氧(ROS)以减少氧化性 DNA、脂质和蛋白质损伤,还能减轻神经炎症、抑制细胞凋亡(apoptosis)、缓解幽门螺杆菌诱导的胃黏膜损伤以及 UVB 诱导的细胞损伤,可用于骨质疏松症、胃炎、缺血性脑卒中及皮肤病的相关研究。

生物实验数据

生物活性 Galloylpaeoniflorin (6'-O-Galloyl paeoniflorin) is an orally active galloylated derivative of Paeoniflorin (MS-U97441) found in the roots of Paeonia lactiflora that possesses multiple anti-inflammatory and antioxidant activities, inhibits RANKL-induced activation of ERK, JNK, c-Fos, c-Jun, and NFATc1 and reduces the expression of osteoclast-specific genes, activates the Nrf2 and PI3K/Akt pathways, suppresses NF-κB activation, and scavenges reactive oxygen species (ROS) to reduce oxidative DNA, lipid, and protein damage, and also attenuates neuroinflammation, inhibits apoptosis, alleviates Helicobacter pylori-induced gastric mucosal injury and UVB-induced cell damage, making it useful for research related to osteoporosis, gastritis, ischemic stroke, and skin diseases.
体外研究
(In Vitro)

Galloylpaeoniflorin (0-160 µM; 96 h) 在孵育 96 小时后,浓度高达 80 µM 时对原代小鼠骨髓来源巨噬细胞/单核细胞无显著细胞毒性。
Galloylpaeoniflorin (10-40 µM; 1-7 days) 可剂量依赖性地抑制 RANKL 诱导的原代小鼠骨髓来源巨噬细胞/单核细胞的破骨细胞生成。
Galloylpaeoniflorin (0-40 µM; 5 days) 可呈剂量依赖性地抑制经 RANKL 刺激的原代小鼠骨髓来源巨噬细胞/单核细胞中破骨细胞特异性基因 (c-Fos、NFATc1、Acp5) 的表达。
Galloylpaeoniflorin (10-40 µM) 可剂量依赖性地抑制由 RANKL 诱导分化为破骨细胞的原代小鼠骨髓来源巨噬细胞/单核细胞的足体带形成、减小细胞体积并降低其多核化水平。
Galloylpaeoniflorin (10-40 µM) 呈剂量依赖性抑制原代小鼠骨髓来源巨噬细胞/单核细胞分化形成的成熟破骨细胞的骨吸收功能。
Galloylpaeoniflorin (10-40 µM) 可呈剂量依赖性清除 RANKL 诱导的原代小鼠骨髓来源巨噬细胞/单核细胞内的活性氧。
Galloylpaeoniflorin (40 µM; 2 h) 可在原代小鼠骨髓来源巨噬细胞/单核细胞中抑制 RANKL 诱导的 ERK 和 JNK MAPK 通路活化,以及下游 c-Fos 和 NFATc1 蛋白的表达,但对 p38 或 NF-κB 通路无影响。
Galloylpaeoniflorin (20-100 μg/mL; 8-24 h) 浓度最高至 60 μg/mL 时,在处理 8、16 或 24 h 后对未感染的人胃上皮细胞 GES-1 无细胞毒性作用,而 80 和 100 μg/mL 的浓度会诱导浓度依赖性细胞毒性。
Galloylpaeoniflorin (60 μg/mL; 8-24 h) 可显著提高 H. pylori 感染的人胃上皮细胞 GES-1 存活率。
Galloylpaeoniflorin (60 μg/mL; 24 h) 可显著抑制 H. pylori 诱导的人胃上皮细胞 GES-1 的早期和晚期凋亡。
Galloylpaeoniflorin (60 μg/mL; 24 h) 可显著降低 H. pylori 感染的人胃上皮细胞 GES-1 中的 ROS、MDA 产生,,并提高其 SOD 活性。
Galloylpaeoniflorin (60 μg/mL; 24 h) 可显著降低 H. pylori 感染的人胃上皮细胞 GES-1 中促炎细胞因子 COX2、TNF-α 和 IL-6 的 mRNA 和蛋白表达,并显著上调抗氧化基因 HMOX1、NQO1 和 MUC1 的 mRNA 和蛋白表达。
Galloylpaeoniflorin (60 μg/mL; 24 h) 可显著抑制 H. pylori 对人胃上皮细胞 GES-1 的黏附。
Galloylpaeoniflorin (60 μg/mL; 24 h) 可显著上调 H. pylori 感染的人胃上皮细胞 GES-1 中的 Nrf2 mRNA 及蛋白表达水平。
Galloylpaeoniflorin (20 μM; UVB 照射前预孵育 1 h、UVB 照射后孵育 24 h) 可显著清除人 HaCaT 角质形成细胞中由 UVB 诱导产生的细胞内活性氧 (ROS)。
Galloylpaeoniflorin (20 μM; UVB 照射前预孵育 1 h、UVB 照射后孵育 2 h) 可减轻 UVB 诱导的人 HaCaT 角质形成细胞 DNA 链断裂
Galloylpaeoniflorin (20 μM; UVB 照射前预孵育 1 h、UVB 照射后孵育 24 h) 可减轻 UVB 诱导的人 HaCaT 角质形成细胞脂质过氧化和蛋白质羰基化
Galloylpaeoniflorin (20 μM; UVB 照射前预孵育 1 h、UVB 照射后孵育 24 h) 可保护人 HaCaT 角质形成细胞免受 UVB 诱导的细胞死亡,将细胞活力从 46%提升至 55%
Galloylpaeoniflorin (20 μM; UVB 照射前预孵育 1 h、UVB 照射后孵育 24 h) 可减轻 UVB 诱导的人 HaCaT 角质形成细胞的凋亡。
Galloylpaeoniflorin (20 μM; UVB 照射前预孵育 1 h、UVB 照射后孵育 24 h) 可减少人 HaCaT 角质形成细胞中由 UVB 诱导的凋亡亚 G1 期亚二倍体细胞,将亚 G1 期细胞群比例从 35%降至 26%。
Galloylpaeoniflorin (20 μM; UVB 照射前预孵育 1 h) 可通过降低活化的半胱天冬酶 9、活化的半胱天冬酶 3 和活化的 PARP 水平,以及恢复 Bcl-2/Bax 蛋白平衡,抑制 UVB 照射的人 HaCaT 角质形成细胞中的线粒体凋亡通路。

Cell Viability Assay

Cell Line: human gastric epithelial immortalized (GES-1) cells (uninfected with H. pylori)
Concentration: 20, 40, 60, 80,100 μg/mL
Incubation Time: 8 h; 16 h; 24 h
Result: Had no effect on GES-1 cell viability at 20, 40, 60 μg/mL after 8, 16, or 24 h of treatment.
Caused a significant reduction in cell viability at 80 μg/mL after 8, 16, and 24 h.
Caused a highly significant reduction in cell viability at 100 μg/mL after 8, 16, and 24 h.

Cell Viability Assay

Cell Line: H. pylori-infected human gastric epithelial immortalized (GES-1) cells
Concentration: 60 μg/mL
Incubation Time: 8 h; 16 h; 24 h
Result: Restored cell viability of H.
pylori-infected GES-1 cells, with significant increases observed at 8 h, 16 h, and 24 h compared to infected, untreated cells.

Apoptosis Analysis

Cell Line: H. pylori-infected human gastric epithelial immortalized (GES-1) cells
Concentration: 60 μg/mL
Incubation Time: 24 h pre-treatment, followed by 8 h H. pylori co-culture
Result: Significantly reduced the percentage of early apoptotic cells and late apoptotic cells compared to infected, untreated cells.

Real Time qPCR

Cell Line: H. pylori-infected human gastric epithelial immortalized (GES-1) cells
Concentration: 60 μg/mL
Incubation Time: 24 h pre-treatment, followed by H. pylori infection
Result: Significantly inhibited mRNA expression of COX2, TNF-α, and IL-6 compared to infected, untreated cells.
Significantly increased mRNA expression of HMOX1 and NQO1 compared to infected, untreated cells.\nSignificantly increased mRNA expression of MUC1 in H.
pylori-infected GES-1 cells.
Had no effect on MUC5AC mRNA expression in H.
pylori-infected GES-1 cells.

Western Blot Analysis

Cell Line: H. pylori-infected human gastric epithelial immortalized (GES-1) cells
Concentration: 60 μg/mL
Incubation Time: 24 h pre-treatment, followed by H. pylori infection
Result: Inhibited protein expression of pro-inflammatory markers COX2, IL-6, and TNF-α compared to infected, untreated cells.
Increased protein expression of antioxidant markers HMOX1 and NQO1 compared to infected, untreated cells.

Cell Viability Assay

Cell Line: human HaCaT keratinocytes
Concentration: 20 μM
Incubation Time: 1 h (pre-incubation before UVB exposure); 24 h (incubation after UVB exposure before analysis)
Result: Increased cell viability from 46% (UVB alone) to 55% (GPF + UVB).
Did not affect cell viability relative to control cells when used alone.

Cell Viability Assay

Cell Line: primary murine bone marrow-derived macrophages/monocytes
Concentration: 5, 10, 20, 40, 80, 160 µM
Incubation Time: 96 h
Result: Showed no significant cytotoxicity at 5- 80 µM.
Slightly reduced cell viability at 160 µM.

Western Blot Analysis

Cell Line: human HaCaT keratinocytes
Concentration: 20 μM
Incubation Time: 1 h (pre-incubation before UVB exposure)
Result: Decreased UVB-induced levels of cleaved caspase 9, cleaved caspase 3, and cleaved poly ADP-ribosyl polymerase (PARP).
Reversed UVB-induced downregulation of anti-apoptotic Bcl-2 protein and upregulation of pro-apoptotic Bax protein.

Western Blot Analysis

Cell Line: primary murine bone marrow-derived macrophages/monocytes
Concentration: 40 µM
Incubation Time: 2 h
Result: Reduced p-ERK, p-JNK expression.
Rduced c-Fos and NFATc1 protein expression.
Had no effect on p38 or NF-κB pathways.

体内研究
(In Vivo)

Galloylpaeoniflorin (10 mg/kg;腹腔注射;每 2 天 1 次;持续 6 周) 可通过提升骨结构参数、减少破骨细胞形成来预防小鼠卵巢切除诱导的骨质疏松症。
Galloylpaeoniflorin (5 mg/kg;灌胃;每日 1 次;预处理给药 2 周) 可通过减轻胃黏膜炎症、增强抗氧化反应及激活 Nrf2 信号通路,缓解 H. pylori 诱导的雄性 C57BL/6 小鼠慢性胃炎。
Galloylpaeoniflorin (2.5-10 mg/kg;腹腔注射;每日 1 次,连续 14 天) 可通过激活 PI3K/Akt/Nrf2 通路,减小梗死体积、改善神经功能、减轻氧化应激、抑制炎症反应并减少神经元凋亡,对雄性 Wistar 大鼠的脑缺血再灌注损伤 (CIRI) 发挥剂量依赖性的神经保护作用。

Animal Model: C57BL/6J (female, 11 weeks old, 19.5 g, bilateral ovariectomy-induced osteoporosis)
Dosage: 10 mg/kg
Administration: i.p.; every 2 days; 6 weeks
Result: Increased bone volume/tissue volume (BV/TV), trabecular number (Tb.
N), trabecular thickness (Tb.
Th), connectivity density (Conn.
Dn), and bone surface (BS) compared to ovariectomized controls.
Decreased trabecular separation (Tb.
Sp) compared to ovariectomized controls.
Significantly reduced the number of TRAP-positive osteoclasts per bone surface compared to ovariectomized controls.
Animal Model: C57BL/6 with H. pylori infection (male, 6-8 weeks old)
Dosage: 5 mg/kg
Administration: p.o.; once daily; 2 weeks pretreatment
Result: Alleviated H.
pylori-induced inflammatory cell infiltration in gastric mucosa and submucosa.
Reduced relative optical density of gastric tissue inflammatory markers COX2 and IL6.
Increased relative optical density of gastric tissue antioxidant markers HMOX1 and NQO1.
Repressed H.
pylori-induced upregulation of COX2, TNF-α, and IL6 mRNA expression in gastric mucosa.
Enhanced H.
pylori-induced upregulation of HMOX1 and NQO1 mRNA expression in gastric mucosa.
Repressed H.
pylori-induced upregulation of COX2, IL6, and TNF-α protein expression in gastric mucosa.
Enhanced H.
pylori-induced upregulation of HMOX1, NQO1, and Nrf2 protein expression in gastric mucosa.
Increased relative optical density of Nrf2 in gastric tissue.
Animal Model: Wistar with CIRI (male, 7-8 months old, 270 g)
Dosage: 2.5 mg/kg; 5 mg/kg; 10 mg/kg
Administration: i.p.; daily; 14 days
Result: Reduced infarct volume by a statistically significant amount compared to untreated CIRI rats.
Reduced neurological score compared to untreated CIRI rats.
Decreased brain malondialdehyde (MDA) levels and increased superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and glutathione (GSH) levels compared to untreated CIRI rats.
Reduced the percentage of Iba1-, p-p38 MAPK-, and p-JNK-positive cells, and reduced IL-1β and TNF-α mRNA expression compared to untreated CIRI rats.
Reduced the percentage of TUNEL-positive cells and caspase-3 activity compared to untreated CIRI rats.
Increased nuclear Nrf2 and heme oxygenase 1 (HO-1) protein expression compared to untreated CIRI rats.
Reduced infarct volume to a greater statistically significant extent compared to untreated CIRI rats.
Reduced neurological score to a greater extent compared to untreated CIRI rats.
Further decreased brain MDA levels and further increased SOD, GSH-Px, and GSH levels compared to untreated CIRI rats.
Further reduced the percentage of Iba1-, p-p38 MAPK-, and p-JNK-positive cells, and further reduced IL-1β and TNF-α mRNA expression compared to untreated CIRI rats.
Further reduced the percentage of TUNEL-positive cells and caspase-3 activity compared to untreated CIRI rats.
Further increased nuclear Nrf2 and HO-1 protein expression compared to untreated CIRI rats.
Reduced infarct volume to the greatest statistically significant extent compared to untreated CIRI rats.
Reduced neurological score to the greatest extent compared to untreated CIRI rats.
Achieved the greatest reduction in brain MDA levels and greatest increases in SOD, GSH-Px, and GSH levels compared to untreated CIRI rats.
Achieved the greatest reduction in the percentage of Iba1-, p-p38 MAPK-, and p-JNK-positive cells, and greatest reduction in IL-1β and TNF-α mRNA expression compared to untreated CIRI rats.
Achieved the greatest reduction in the percentage of TUNEL-positive cells and caspase-3 activity compared to untreated CIRI rats.
Achieved the greatest increases in nuclear Nrf2 and HO-1 protein expression compared to untreated CIRI rats.
Attenuated all protective effects when rats were pretreated with Ly294002 (MS-X98356).
性状 固体
颜色 White to off-white

化学信息

分子量 632.57
分子式 C30H32O15
CAS No. 122965-41-7
别名 6'-O-Galloyl paeoniflorin

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.16 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, sealed storage, away from moisture and light

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (158.09 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.5809 mL7.9043 mL15.8085 mL39.5213 mL
5 mM0.3162 mL1.5809 mL3.1617 mL7.9043 mL
10 mM0.1581 mL0.7904 mL1.5809 mL3.9521 mL
15 mM0.1054 mL0.5270 mL1.0539 mL2.6348 mL
20 mM0.0790 mL0.3952 mL0.7904 mL1.9761 mL
25 mM0.0632 mL0.3162 mL0.6323 mL1.5809 mL
30 mM0.0527 mL0.2635 mL0.5270 mL1.3174 mL
40 mM0.0395 mL0.1976 mL0.3952 mL0.9880 mL
50 mM0.0316 mL0.1581 mL0.3162 mL0.7904 mL
60 mM0.0263 mL0.1317 mL0.2635 mL0.6587 mL
80 mM0.0198 mL0.0988 mL0.1976 mL0.4940 mL
100 mM0.0158 mL0.0790 mL0.1581 mL0.3952 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础